WO2019031618A8 - アゾールで置換されたピリジン化合物 - Google Patents

アゾールで置換されたピリジン化合物 Download PDF

Info

Publication number
WO2019031618A8
WO2019031618A8 PCT/JP2018/030456 JP2018030456W WO2019031618A8 WO 2019031618 A8 WO2019031618 A8 WO 2019031618A8 JP 2018030456 W JP2018030456 W JP 2018030456W WO 2019031618 A8 WO2019031618 A8 WO 2019031618A8
Authority
WO
WIPO (PCT)
Prior art keywords
formula
azole
pyridine compound
compound substituted
represented
Prior art date
Application number
PCT/JP2018/030456
Other languages
English (en)
French (fr)
Other versions
WO2019031618A1 (ja
Inventor
宏明 田中
円 川村
まこと 濱田
陽平 小橋
勇次 伊藤
一瑛 鈴木
綾子 坊野
浩介 舟山
Original Assignee
大正製薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2019535736A priority Critical patent/JP7052798B2/ja
Priority to US16/637,595 priority patent/US11365192B2/en
Priority to MX2020001615A priority patent/MX2020001615A/es
Priority to AU2018312680A priority patent/AU2018312680A1/en
Application filed by 大正製薬株式会社 filed Critical 大正製薬株式会社
Priority to CA3072420A priority patent/CA3072420A1/en
Priority to EP18843913.7A priority patent/EP3666766A4/en
Priority to RU2020109674A priority patent/RU2020109674A/ru
Priority to SG11202000976TA priority patent/SG11202000976TA/en
Priority to KR1020207002413A priority patent/KR20200038457A/ko
Priority to BR112020002519-4A priority patent/BR112020002519A2/pt
Priority to CN201880052001.7A priority patent/CN110914254A/zh
Publication of WO2019031618A1 publication Critical patent/WO2019031618A1/ja
Publication of WO2019031618A8 publication Critical patent/WO2019031618A8/ja
Priority to IL272482A priority patent/IL272482A/en
Priority to PH12020500292A priority patent/PH12020500292A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本発明は、２０－ＨＥＴＥを産生する酵素を阻害する作用を有する下記式［Ｉ］で表される化合物又はその製薬学的に許容される塩を提供する。（上記式［Ｉ］中、下記式［ＩＩ］で表される構造は、下記式群［ＩＩＩ］で表される構造のいずれかを示し；Ｒ１、Ｒ２、Ｒ３、及びＲ４は、独立して、水素原子、フッ素原子、メチル等を示し、Ｒ５は、下記式群［ＩＶ］で表される構造のいずれかを示す：。）
PCT/JP2018/030456 2017-08-10 2018-08-10 アゾールで置換されたピリジン化合物 WO2019031618A1 (ja)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP18843913.7A EP3666766A4 (en) 2017-08-10 2018-08-10 COMPOUND OF PYRIDINE SUBSTITUTED BY AN AZOLE
MX2020001615A MX2020001615A (es) 2017-08-10 2018-08-10 Compuestos de piridina sustituidos con azol.
AU2018312680A AU2018312680A1 (en) 2017-08-10 2018-08-10 Pyridine compound substituted with azole
SG11202000976TA SG11202000976TA (en) 2017-08-10 2018-08-10 Pyridine compound substituted with azole
CA3072420A CA3072420A1 (en) 2017-08-10 2018-08-10 Pyridine compound substituted with azole
US16/637,595 US11365192B2 (en) 2017-08-10 2018-08-10 Pyridine compound substituted with azole
RU2020109674A RU2020109674A (ru) 2017-08-10 2018-08-10 Пиридин, замещенный азолом
JP2019535736A JP7052798B2 (ja) 2017-08-10 2018-08-10 アゾールで置換されたピリジン化合物
KR1020207002413A KR20200038457A (ko) 2017-08-10 2018-08-10 아졸로 치환된 피리딘 화합물
BR112020002519-4A BR112020002519A2 (pt) 2017-08-10 2018-08-10 composto de piridina substituído por azol
CN201880052001.7A CN110914254A (zh) 2017-08-10 2018-08-10 唑类取代的吡啶化合物
IL272482A IL272482A (en) 2017-08-10 2020-02-05 A pyridine compound is transformed with an azole
PH12020500292A PH12020500292A1 (en) 2017-08-10 2020-02-10 Pyridine compound substituted with azole

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-171584 2017-08-10
JP2017171584 2017-08-10

Publications (2)

Publication Number Publication Date
WO2019031618A1 WO2019031618A1 (ja) 2019-02-14
WO2019031618A8 true WO2019031618A8 (ja) 2019-04-11

Family

ID=65271252

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/030456 WO2019031618A1 (ja) 2017-08-10 2018-08-10 アゾールで置換されたピリジン化合物

Country Status (15)

Country Link
US (1) US11365192B2 (ja)
EP (1) EP3666766A4 (ja)
JP (1) JP7052798B2 (ja)
KR (1) KR20200038457A (ja)
CN (1) CN110914254A (ja)
AU (1) AU2018312680A1 (ja)
BR (1) BR112020002519A2 (ja)
CA (1) CA3072420A1 (ja)
IL (1) IL272482A (ja)
MX (1) MX2020001615A (ja)
PH (1) PH12020500292A1 (ja)
RU (1) RU2020109674A (ja)
SG (1) SG11202000976TA (ja)
TW (1) TW201920134A (ja)
WO (1) WO2019031618A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020162612A1 (ja) * 2019-02-08 2020-08-13 大正製薬株式会社 ヘテロアリールで置換されたピリジン化合物
JP7250738B2 (ja) * 2020-07-22 2023-04-03 信越化学工業株式会社 ３，３－ジメチル－１－ブテン－１，４－ジカルボキシレート化合物及び１，３，３－トリメチル－１－ブテン－１，４－ジカルボキシレート化合物、並びに、これらを用いた５，５－ジメチル－２－オキソ－３－シクロペンテン－１－カルボキシレート化合物及び３，５，５－トリメチル－２－オキソ－３－シクロペンテン－１－カルボキシレート化合物の製造方法
CN115073308A (zh) * 2021-03-15 2022-09-20 苏州信礼发医药技术有限公司 1-氨甲基-1-环丙醇的合成方法
GB202108544D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
CN115557898B (zh) * 2021-07-01 2024-08-20 诸葛国琴 一种咪唑类化合物、其中间体及应用
CN114380682A (zh) * 2021-10-27 2022-04-22 上海毕得医药科技股份有限公司 一种2,3-二氟-4-甲氧基苯乙酸合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1226819T3 (da) 1999-11-01 2006-05-22 Taisho Pharmaceutical Co Ltd Inhibitor for 20-HETE-producerende enzym
JP2004502672A (ja) 2000-06-29 2004-01-29 アボット・ラボラトリーズ 細胞接着阻害抗炎症剤および免疫抑制剤としてのアリールフェニルシクロプロピルスルフィド誘導体およびその使用
JPWO2003022821A1 (ja) 2001-09-06 2004-12-24 大正製薬株式会社 ２０−ｈｅｔｅ産生酵素阻害作用を有するヘテロ環誘導体
JP2004262890A (ja) 2003-03-04 2004-09-24 Taisho Pharmaceut Co Ltd ２０−ｈｅｔｅ産生阻害作用を有するアゾール誘導体
CA2522266A1 (en) 2003-04-14 2004-10-28 Nippon Soda Co., Ltd. Phenylazole compound, production process therefor and antioxidant
EP1650206A4 (en) 2003-08-01 2006-12-20 Nippon Soda Co PHENYLAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND ANTIOXIDANTS
AR076687A1 (es) 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
EP3029035B1 (en) 2013-07-31 2018-05-30 Sumitomo Chemical Company, Limited Tetrazolinone compound, and use thereof
JP6351043B2 (ja) 2015-08-04 2018-07-04 株式会社ユニバーサルエンターテインメント 遊技機
BR112018015760A2 (pt) * 2016-02-15 2019-01-02 Taisho Pharmaceutical Co., Ltd. composto de piridina substituído por azol

Also Published As

Publication number Publication date
SG11202000976TA (en) 2020-03-30
BR112020002519A2 (pt) 2020-08-04
MX2020001615A (es) 2020-07-13
RU2020109674A (ru) 2021-09-13
WO2019031618A1 (ja) 2019-02-14
US11365192B2 (en) 2022-06-21
TW201920134A (zh) 2019-06-01
KR20200038457A (ko) 2020-04-13
EP3666766A4 (en) 2021-03-24
JPWO2019031618A1 (ja) 2020-07-30
CN110914254A (zh) 2020-03-24
IL272482A (en) 2020-03-31
US20210122741A1 (en) 2021-04-29
EP3666766A1 (en) 2020-06-17
CA3072420A1 (en) 2019-02-14
JP7052798B2 (ja) 2022-04-12
AU2018312680A1 (en) 2020-03-19
PH12020500292A1 (en) 2021-01-25

Similar Documents

Publication Publication Date Title
WO2019031618A8 (ja) アゾールで置換されたピリジン化合物
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
PH12018500343A1 (en) Heterocyclic amides as kinase inhibitors
AU2018312326A2 (en) Heterocyclic compound and use thereof
PH12017502171A1 (en) PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
WO2014144545A3 (en) Substituted benzoxazoles and methods of use thereof
MX2016007522A (es) Estimuladores de guanilato ciclasa soluble (sgc).
MX2022002976A (es) Inhibidores selectivos de jak1.
MY193597A (en) Novel pyrrolidine compound and application as melanocortin receptor agonist
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
JOP20200030A1 (ar) مركب خماسي الحلقة
WO2018104729A8 (en) Ketamine derivatives
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
WO2018039077A8 (en) Therapeutic compounds
MX2021015514A (es) Compuesto heterociclico.
WO2018194181A8 (en) HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF ACETYLCHOLINE RECEPTORS
SG11201810725WA (en) Novel β-lactamase inhibitors
PH12020550649A1 (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
TW201612165A (en) Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound
MX2015007309A (es) Derivado de hidantoina.
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
PH12019500492A1 (en) Imide compound and use thereof
PH12018501138A1 (en) Pest control composition including iminopyridine derivative
MX2019015747A (es) Compuesto heterociclico.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18843913

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019535736

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3072420

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112020002519

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2018312680

Country of ref document: AU

Date of ref document: 20180810

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018843913

Country of ref document: EP

Effective date: 20200310

ENP Entry into the national phase

Ref document number: 112020002519

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20200206